• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotic Maintenance: How Long is Enough?

Antipsychotic Maintenance: How Long is Enough?

January 13, 2020
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Your 58-year-old patient started risperidone to augment lithium 2 years ago. It got her out of a severe mania, and she has stayed well since then. Now she’s worried about long-term risks and wondering if it’s time to come off.


Augmentation with an atypical antipsychotic may offer rapid relief from mania and depression, but antipsychotics’ potential side effects are substantial. They include hyperlipidemia, diabetes, obesity, and tardive dyskinesia, the latter increasing at a rate of 2.6% with each year of use. These side effects tend to build gradually over time, so it’s important to know when it’s clinically appropriate to try stopping the antipsychotic and possibly continuing solo with a mood stabilizer or antidepressant.


Around a dozen industry-supported trials have looked at this question in both bipolar and unipolar disorders. These studies all followed a similar design: They started with patients who recovered with antipsychotic augmentation and then tested what happens when the antipsychotic is withdrawn after 2–3 months of treatment. Typically half the patients continued with the antipsychotic and the other half were switched to placebo. The patients were then followed for a long stretch—from 6 months to 2 years—and the rate of relapse was carefully tracked (Lindström L et al, J Affect Disord 2017;213:138–150; Kato M et al, CNS Drugs 2013;27 Suppl 1:S11–19).


The consensus of these studies is that continuing the antipsychotic prevents relapse into new mood episodes, but there’s a catch. Most of these studies withdrew the antipsychotic within the first few months after recovery, which is a particularly vulnerable time for patients. What if the antipsychotic were stopped later, after 6 months of recovery?


We could find only a single study that looked at this question, and it was in bipolar I disorder. This non-industry-sponsored study enrolled 159 patients who had recovered from bipolar mania after their mood stabilizers were augmented with an antipsychotic, either risperidone or olanzapine. Patients were then randomized into 1 of 3 groups: 1) Continue the antipsychotic for a year; 2) Switch to a placebo after 2–6 weeks of recovery; or 3) Switch to a placebo after 6 months of recovery. All groups were kept on their original mood stabilizer (lithium or valproate). The result: Patients who stopped the antipsychotic after 6 months had the same risk of relapse as those who stayed on the antipsychotic (65%), but the risk was significantly higher when the medication was stopped after 2–6 weeks (87%). Those are high relapse rates across the board, but that’s not uncommon in mania (Yatham LN et al, Mol Psychiatry 2016;21(8):1050–1056).


That study suggests that antipsychotics can be safely discontinued after 6 months of recovery from mania. In depression, antipsychotics are overall less effective as preventative agents than they are for mania. Among the agents studied, only quetiapine has successfully prevented depression in controlled trials, 2 in bipolar disorder and 1 in unipolar (Liebowitz M et al, Depress Anxiety 2010;27:964–976; Lindström L et al, J Affect Disord 2017;213:138–150). Those trials tested discontinuation at 3 months. No one has tested whether 6 months of maintenance would be adequate in depression, but we have a hint that it might from the studies of antidepressant discontinuation. In those trials, most of the relapses were due to discontinuation of the antidepressant before 6 months of stabilization, according to a meta-analysis of 45 controlled trials (Baldessarini RJ et al, J Clin Psychopharmacol 2015;35(1):75–76).


In practice, I usually wait 6 months before trying antipsychotic discontinuation. The decision is collaborative and different for each patient. If we decide to come off, I’ll taper slowly, lowering the dose every 2 weeks. I’ll encourage the patient to build habits known to prevent mood episodes, such as mindfulness, exercise, the Mediterranean diet, and regular sleep and wake times. If the taper does not work, I may try again after 1–2 years. About half the time, the second attempt is a success.


TCPR Verdict: In mood disorders, wait at least 6 months after recovery before attempting to discontinue an adjunctive antipsychotic. Taper slowly, watch for relapse, and encourage lifestyle changes to prevent new episodes.

General Psychiatry
KEYWORDS antidepressant-augmentation antidepressants antipsychotics bipolar_disorder deprescribing depression depressive_disorder mania metabolic-syndrome mood_stabilizers olanzapine psychopharmacology psychopharmacology_tips risperidone side-effects tardive-dyskinesia
Aiken
Chris Aiken, MD.

Ask the Editor: Three Significant Food Interactions with ADHD Medications

More from this author
www.thecarlatreport.com
Issue Date: January 13, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Esketamine, TCPR, January 2020
How to Treat Tardive Dyskinesia
Getting Uncomfortable with Esketamine
Antipsychotic Maintenance: How Long is Enough?
TMS: Deeper is not Better
In Brief: Antipsychotic Update
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.